Corticosteroid monotherapy versus combined cytarabine continuous rate infusion and corticosteroid therapy in dogs with meningoencephalitis of unknown origin: A blinded, randomized, controlled trial
Journal of Veterinary Internal Medicine · 2024
DOI: 10.1111/jvim.17088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, 2024. Verfasst von Bethan S Jones und 6 weiteren Autor:innen. Beteiligte Einrichtung: Langford Vets Small Animal Hospital, Bristol, United Kingdom. Hauptthemen laut MEDLINE: Cytarabine, Dog Diseases, Meningoencephalitis, Drug Therapy, Combination. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Treatment options available for meningoencephalitis of unknown origin (MUO) in dogs are suboptimal, and currently, no single treatment protocol appears to be superior.
Objectives
Compare neurological deterioration rates at 7 days between dogs with MUO treated with corticosteroids alone or combined with cytosine arabinoside (CA) continuous rate infusion (CRI) and compare clinical deterioration and survival at 30 and 100 days. Animals Sixty-nine dogs with magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) features or both compatible with MUO.
Methods
Parallel, blinded, randomized controlled trial. Simple randomization into 2 treatment groups: 4 mg/kg/day prednisolone (or dexamethasone equivalent) for 2 days or 200 mg/m2 CA CRI over 8 hours plus 2 mg/kg/day prednisolone. Blinding of the treatment protocol was carried out using reversible redaction of clinical records, and treatment failure was defined as deterioration of neurological assessment or death. Using intention-to-treat analysis, proportions failing treatment at 7, 30, and 100 days were compared using Fisher's exact test. All-cause mortality at 100 days was compared using Kaplan-Meier survival curves.
Results
Thirty-five dogs were allocated to corticosteroid only, and 34 dogs were allocated to combined CA CRI and corticosteroid. Proportions failing treatment at 7, 30, and 100 days were 7/35 (20%), 9/35 (26%), and 15/35 (43%) in the corticosteroid-only group and 8/34 (24%), 11/34 (32%), and 23/34 (68%) in the corticosteroid and CA CRI group. All-cause mortality at 100 days was not significantly different between groups (P = .62). Clinically relevant treatment-related adverse effects were not observed. Conclusions and Clinical Importance We found no difference in outcome between corticosteroid monotherapy and combined cytarabine CRI and corticosteroid therapy at 7, 30, and 100 days after diagnosis in dogs with MUO.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Langford Vets Small Animal Hospital, Bristol, United Kingdom.
ORCID-Profile: Bethan S Jones, Thomas Harcourt-Brown
Zitieren
APA
Jones, B. S., Liebel, F. X., Fadda, A., Martin, S., Lawn, R., Lazzerini, K., & Harcourt-Brown, T. (2024). Corticosteroid monotherapy versus combined cytarabine continuous rate infusion and corticosteroid therapy in dogs with meningoencephalitis of unknown origin: A blinded, randomized, controlled trial. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17088
Vancouver
Jones BS, Liebel FX, Fadda A, Martin S, Lawn R, Lazzerini K, et al. Corticosteroid monotherapy versus combined cytarabine continuous rate infusion and corticosteroid therapy in dogs with meningoencephalitis of unknown origin: A blinded, randomized, controlled trial. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.17088
BibTeX
@article{Jones2024,
author = {Jones, Bethan S and Liebel, Francois Xavier and Fadda, Angela and Martin, Sophie and Lawn, Richard and Lazzerini, Kali and Harcourt-Brown, Thomas},
title = {Corticosteroid monotherapy versus combined cytarabine continuous rate infusion and corticosteroid therapy in dogs with meningoencephalitis of unknown origin: A blinded, randomized, controlled trial},
journal = {Journal of Veterinary Internal Medicine},
year = {2024},
doi = {10.1111/jvim.17088}
}
EUVIMED